Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Accelerate Biotech Process Development

As the biopharma landscape evolves, companies face increasing pressure to accelerate time-to-market while meeting shifting regulatory standards. This event explores how to navigate these demands [...]

Go to Top